Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Skin & Soft Tissues Diseases specialty page provides skin & soft tissue-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Omadacycline: A Potential Fluoroquinolone Replacement?
Jason Gallagher, PharmD, discusses how omadacycline could potentially replace fluoroquinolone use in the treatment of complicated skin infections and community-acquired pneumonia.
Paradigm Shift in Treatment for ABSSSI
Yoav Golan, MD, discusses the paradigm shift occurring in treatment for ABSSSI and how to motivate clinicians to buy into new programs and protocols.
Establishing Real-World Protocols for OPAT
Panelists discuss the importance of establishing real-world protocols for patient identification, qualification, and eligibility for outpatient parenteral antibiotic therapy.
The Growing Burden of ABSSSI
Bruce Jones, PharmD, BCPS, discusses the growing burden of ABSSSI and why there have been an influx of MRSA cases.
Treatment Challenges Remain as ABSSSI Incidence Continues to Grow
Yoav Golan, MD, discusses trends in the incidence of acute bacterial skin and skin structure infections, standard protocols for treatment, and the challenges clinicians continue to face.
Oral Antibiotic Compliance for ABSSSI
Panelists emphasize the importance of patient education, patient compliance, oral antibiotic adherence, and managing expectations of prescriptions for acute bacterial skin and skin structure infections.
Who is Not a Good Candidate for MRSA Prodrug TXA709?
Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.
Why Was a Specific Meningococcal Disease Vaccine Recommended for the 2016 Rutgers Outbreak?
The CDC offers insight into why a rare exception to the general recommendation of either brand of MenB vaccine had been made for the Rutgers outbreak in 2016.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?